Pediatric Cancer Immunotherapy

U.S. News & World Report - CancerImmunotherapy is a promising new treatment option for certain kinds of childhood cancers. Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy that uses the body’s own immune system to fight cancer.

Stanford Children’s Health combines cutting-edge immunotherapy research and an experienced team of compassionate doctors to provide the best immunotherapy treatment options for children and young adults with cancer. From KYMRIAH, the first FDA-approved CAR T-cell therapy, to clinical trials available only at Stanford, we offer patients excellent cancer care using the latest therapies.

Our care team includes world-renowned pediatric oncologists, led by Crystal Mackall, MD, who was part of a team at the National Institutes of Health that developed some of the earliest immunotherapy treatments. Our pediatric-specific research program helps us bring cures from the lab bench to the patient’s bedside. Dr. Mackall also leads the Pediatric Cancer Immunotherapy Trials Network, where our experts continually collaborate with other doctors and researchers to bring our patients the best possible care.